株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

眼薬の世界市場予測

Global Ophthalmic Drug Market Forecast 2019-2027

発行 Inkwood Research 商品コード 444523
出版日 ページ情報 英文 124 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.71円で換算しております。
Back to Top
眼薬の世界市場予測 Global Ophthalmic Drug Market Forecast 2019-2027
出版日: 2019年06月10日 ページ情報: 英文 124 Pages
概要

当レポートでは、世界の眼薬市場について分析し、市場影響要因、処方種類、エンドユーザー、および地域別の詳細な市場動向、市場競争動向、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 分析範囲

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 市場決定要因

  • 市場抑制要因
  • 市場機会

第5章 世界の眼薬市場:処方種類別

  • 世界における眼薬の処方薬市場
  • 世界における眼薬のOTC薬 (市販薬) 市場

第6章 世界の眼薬市場:エンドユーザー別

  • 世界の病院における眼薬市場
  • 世界の眼科における眼薬市場
  • 世界の診断センターにおける眼薬市場
  • 世界の患者向け眼薬市場

第7章 主な分析

  • バリューチェーン分析
    • 研究開発
    • 製造
    • マーケティング・流通
  • ポーターのファイブフォース分析
  • シーソー分析

第8章 地域分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • ロシア
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア
  • 中東・アフリカ
  • 中南米

第9章 競合状況

図表

LIST OF TABLES

  • TABLE 1 GLOBAL OPHTHALMIC DRUG MARKET REVENUE BY REGION 2019-2027 ($ MILLION)
  • TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
  • TABLE 3 EYE DRUGS GONE OFF-PATENT
  • TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL DRY EYE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL OPHTHALMIC DRUGS MARKET BY DRY EYE 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL GLAUCOMA MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL INFECTION/INFLAMMATION/ALLERGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL RETINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL DIABETIC RETINOPATHY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL OTHER RETINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL OTHER INDICATION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL OPHTHALMIC DRUGS MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL PRESCRIPTION DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL OVER-THE-COUNTER DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL HOSPITAL PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 20 GLOBAL DRUG STORES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 21 GLOBAL ONLINE PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 22 GLOBAL OTHER DISTRIBUTION CHANNEL MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 23 GLOBAL OPHTHALMIC DRUGS MARKET BY DOSAGE FORM 2019-2027 ($ MILLION)
  • TABLE 24 GLOBAL LIQUID OPHTHALMIC DRUG FORMS PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 25 GLOBAL SOLID OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 26 GLOBAL SEMISOLID OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 27 GLOBAL MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 28 GLOBAL OTHER OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 29 GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTIC CLASS 2019-2027 ($ MILLION)
  • TABLE 30 GLOBAL ANTI-GLAUCOMA MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 31 GLOBAL ANTI-INFECTIVE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 32 GLOBAL ANTI-INFLAMMATORY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 33 GLOBAL ANTI-ALLERGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 34 GLOBAL OPHTHALMIC DRUGS MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
  • TABLE 35 GLOBAL BIOLOGICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 36 GLOBAL CELL THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 37 GLOBAL GENE THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 38 GLOBAL DRUG DELIVERY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 39 GLOBAL SMALL MOLECULE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 40 GLOBAL OTHER TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 41 GLOBAL OPHTHALMIC DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 42 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 43 EUROPE OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 44 ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
  • FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
  • FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
  • FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
  • FIGURE 5 HEALTHCARE EXPENDITURE CATARACT SURGERIES ON THE RISE
  • FIGURE 6 GLOBAL OPHTHALMIC DRUGS MARKET BY GLAUCOMA2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL OPHTHALMIC DRUGS MARKET BY INFECTION/ INFLAMMATION/ ALLERGY 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY RETINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL RETINAL DISORDERS MARKET BY WET AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL RETINAL DISORDERS MARKET BY DRY AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL RETINAL DISORDERS MARKET BY DIABETIC RETINOPATHY 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL RETINAL DISORDERS MARKET BY OTHER RETINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER INDICATION 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION DRUGS 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL OPHTHALMIC DRUGS MARKET BY OVER-THE-COUNTER DRUGS 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL OPHTHALMIC DRUGS MARKET BY HOSPITAL PHARMACIES 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG STORES 2019-2027 ($ MILLION)
  • FIGURE 18 GLOBAL OPHTHALMIC DRUGS MARKET BY ONLINE PHARMACIES 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
  • FIGURE 20 GLOBAL OPHTHALMIC DRUGS MARKET BY LIQUID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 21 GLOBAL OPHTHALMIC DRUGS MARKET BY SOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 22 GLOBAL OPHTHALMIC DRUGS MARKET BY SEMISOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 23 GLOBAL OPHTHALMIC DRUGS MARKET BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS 2019-2027 ($ MILLION)
  • FIGURE 24 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
  • FIGURE 25 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-GLAUCOMA 2019-2027 ($ MILLION)
  • FIGURE 26 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-INFECTIVE 2019-2027 ($ MILLION)
  • FIGURE 27 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-INFLAMMATORY 2019-2027 ($ MILLION)
  • FIGURE 28 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-ALLERGY 2019-2027 ($ MILLION)
  • FIGURE 29 GLOBAL OPHTHALMIC DRUGS MARKET BY BIOLOGICS 2019-2027 ($ MILLION)
  • FIGURE 30 GLOBAL OPHTHALMIC DRUGS MARKET BY CELL THERAPY 2019-2027 ($ MILLION)
  • FIGURE 31 GLOBAL OPHTHALMIC DRUGS MARKET BY GENE THERAPY 2019-2027 ($ MILLION)
  • FIGURE 32 GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG DELIVERY 2019-2027 ($ MILLION)
  • FIGURE 33 GLOBAL OPHTHALMIC DRUGS MARKET BY SMALL MOLECULE 2019-2027 ($ MILLION)
  • FIGURE 34 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 35 THE UNITED STATES POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
  • FIGURE 36 THE UNITED STATES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 37 CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 38 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
  • FIGURE 39 EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 40 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
  • FIGURE 41 GERMANY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 42 THE UNITED KINGDOM OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 43 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
  • FIGURE 44 POPULATION AGED 65 AND ABOVE IN FRANCE (% OF TOTAL)
  • FIGURE 45 FRANCE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 46 ITALY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 47 SPAIN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 48 REST OF EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 49 ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 50 CHINA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 51 INDIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 52 JAPAN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 53 SOUTH KOREA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 54 NUMBER OF YEARS FOR PERCENTAGE, AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
  • FIGURE 55 AUSTRALIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 56 REST OF ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 57 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 58 LATIN AMERICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 59 AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)
目次
Product Code: 2970

KEY FINDINGS

The global ophthalmic drugs market is anticipated to grow at a CAGR of 4.31% between 2019 and 2027 to generate revenue of $38,473 million by 2027. An existing predominance and increase in the number of eye disorders with a growing geriatric population all over the world are the primary drivers responsible for market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.

MARKET INSIGHTS

The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. Vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause of half-blindness and decreased vision is the cataract, which has the highest percentage accountable for worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted consumer spending, thus indirectly driving the ophthalmic drugs market.

REGIONAL INSIGHTS

North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for the second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in the aged population and the existence of dominant market players in the regions are driving the regional markets.

COMPETITIVE INSIGHTS

The predominant ophthalmic drugs companies in the global market are Bayer, Allergan Inc., Sun Pharmaceuticals Industries, Ltd., Valeant, GlaxoSmithKline, Apollo Endosurgery, Regeneron, Senju Pharmaceutical Co., Ltd., Abbott Laboratories, Merck & Co., Novartis AG, Roche Holding AG, Pfizer Inc., Cipla Pharmaceuticals, Eyegate Pharmaceuticals, and Johnson and Johnson.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. RETINAL DISORDERS ARE THE HIGHEST REVENUE GENERATING INDICATION
    • 3.2.2. PRESCRIPTION DRUGS ARE THE FASTEST GROWING OPHTHALMIC DRUGS TYPE
    • 3.2.3. HOSPITAL PHARMACIES ARE THE MAJORLY USED DISTRIBUTION CHANNEL
    • 3.2.4. LIQUID OPHTHALMIC DRUG FORMS ARE THE WIDELY USED DOSAGE FORM
    • 3.2.5. ANTI-ALLERGY THERAPEUTIC CLASS IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD
    • 3.2.6. SMALL MOLECULE TECHNOLOGY IS USED FOR THE TREATMENT OF EYE DISEASES

4. MARKET DETERMINANTS

  • 4.1. MARKET DEFINITION AND SCOPE
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASING GERIATRIC POPULATION
    • 4.2.2. TECHNOLOGICAL ADVANCEMENT
    • 4.2.3. RISING PREVALENCE OF EYE DISORDERS
    • 4.2.4. INCREASED HEALTHCARE EXPENDITURE
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. RENOWNED DRUGS GOING OFF-PATENT
    • 4.3.2. DELAY IN DRUG APPROVALS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
    • 4.4.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. SIDE EFFECTS RELATED TO THE OPHTHALMIC DRUGS

5. MARKET BY INDICATION

  • 5.1. DRY EYE
  • 5.2. GLAUCOMA
  • 5.3. INFECTION/INFLAMMATION/ALLERGY
  • 5.4. RETINAL DISORDERS
    • 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
    • 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
    • 5.4.3. DIABETIC RETINOPATHY
    • 5.4.4. OTHER RETINAL DISORDERS
  • 5.5. OTHER INDICATION

6. MARKET BY TYPE

  • 6.1. PRESCRIPTION DRUGS
  • 6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DISTRIBUTION CHANNEL

  • 7.1. HOSPITAL PHARMACIES
  • 7.2. DRUG STORES
  • 7.3. ONLINE PHARMACIES
  • 7.4. OTHER DISTRIBUTION CHANNEL

8. MARKET BY DOSAGE FORM

  • 8.1. LIQUID OPHTHALMIC DRUG FORMS
  • 8.2. SOLID OPHTHALMIC DRUG FORMS
  • 8.3. SEMISOLID OPHTHALMIC DRUG FORMS
  • 8.4. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
  • 8.5. OTHER OPHTHALMIC DRUG FORMS

9. MARKET BY THERAPEUTIC CLASS

  • 9.1. ANTI-GLAUCOMA
  • 9.2. ANTI-INFECTIVE
  • 9.3. ANTI-INFLAMMATORY
  • 9.4. ANTI-ALLERGY

10. MARKET BY TECHNOLOGY

  • 10.1. BIOLOGICS
  • 10.2. CELL THERAPY
  • 10.3. GENE THERAPY
  • 10.4. DRUG DELIVERY
  • 10.5. SMALL MOLECULE
  • 10.6. OTHER TECHNOLOGY

11. KEY ANALYTICS

  • 11.1. PORTER'S FIVE FORCES ANALYSIS
    • 11.1.1. BARGAINING POWER OF BUYERS
    • 11.1.2. BARGAINING POWER OF SUPPLIER
    • 11.1.3. THREATS OF NEW ENTRANTS
    • 11.1.4. THREATS OF SUBSTITUTES
    • 11.1.5. COMPETITIVE RIVALRY
  • 11.2. VALUE CHAIN ANALYSIS
    • 11.2.1. RESEARCH AND DEVELOPMENT
    • 11.2.2. MANUFACTURING
    • 11.2.3. MARKETING AND DISTRIBUTION
  • 11.3. REGULATORY FRAMEWORK
  • 11.4. OPPORTUNITY MATRIX

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. THE UNITED STATES
    • 12.1.2. CANADA
  • 12.2. EUROPE
    • 12.2.1. GERMANY
    • 12.2.2. THE UNITED KINGDOM
    • 12.2.3. FRANCE
    • 12.2.4. ITALY
    • 12.2.5. SPAIN
    • 12.2.6. REST OF EUROPE
  • 12.3. ASIA PACIFIC
    • 12.3.1. CHINA
    • 12.3.2. INDIA
    • 12.3.3. JAPAN
    • 12.3.4. SOUTH KOREA
    • 12.3.5. AUSTRALIA
    • 12.3.6. REST OF ASIA PACIFIC
  • 12.4. REST OF WORLD
    • 12.4.1. MIDDLE EAST & AFRICA
    • 12.4.2. LATIN AMERICA

13. COMPANY PROFILES

  • 13.1. ABBOTT LABORATORIES
  • 13.2. ALLERGAN INC.
  • 13.3. JOHNSON AND JOHNSON
  • 13.4. BAYER
  • 13.5. VALEANT
  • 13.6. REGENERON
  • 13.7. PFIZER INC.
  • 13.8. MERCK & CO.
  • 13.9. NOVARTIS AG
  • 13.10. GLAXOSMITHKLINE
  • 13.11. EYEGATE PHARMACEUTICALS
  • 13.12. APOLLO ENDOSURGERY
  • 13.13. ROCHE HOLDING AG
  • 13.14. CIPLA PHARMACEUTICALS
  • 13.15. SENJU PHARMACEUTICAL CO., LTD.
  • 13.16. SUN PHARMACEUTICALS INDUSTRIES, LTD.
Back to Top